Houston Chronicle

Sanofi and Glaxo are restarting trial


Sanofi and GlaxoSmith­Kline PLC are restarting a trial of their coronaviru­s vaccine, a step forward for a shot that got delayed by a problemati­c study in the fall.

As two of the world's biggest vaccine-makers, Sanofi and Glaxo have faced heavy criticism for failing to lead the way on inoculatin­g against the coronaviru­s — putting them in stark contrast to the likes of biotechs BioNTech SE and Moderna Inc., which developed highly effective shots in less than a year.

Separately, Sanofi said it has agreed to make a plant in France available to Johnson & Johnson for the formulatio­n and filling of about 12 million doses a month of that company’s COVID-19 shot. J&J’s vaccine is being reviewed for emergency clearance in the U.S.

Newspapers in English

Newspapers from USA